Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
14 March 2025
| Name: | NARHEX LIFE SCIENCES LIMITED (NLS) (This company subsequently changed its name and is now RESAPP HEALTH LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 12 January 2005 | ||||||
| Subsequent Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now RESAPP HEALTH LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now RESAPP HEALTH LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now RESAPP HEALTH LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| RESAPP HEALTH LIMITED | 08/07/2015 | |
| NARHEX LIFE SCIENCES LIMITED | 08/07/2015 |
REGISTRY:
Link Market Services Perth
Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000
Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
name changed to ResApp Health Limited | 08/07/2015 |
The Company is pleased to announce that the Share Sale Agreement dated 20 February 2015 between the Company, ResApp Diagnostics Pty Ltd ("ResApp"), the Shareholders of ResApp and UniQuest Pty Ltd has completed with the Company acquiring 100% of ResApp. | 02/07/2015 |
Narhex Life Sciences Limited ("Company") is pleased to announce that its Capital Raising has closed oversubscribed, with funds totalling $4,000,000 having been raised under the Company's Replacement Prospectus dated 26 May 2015. The Company will now proceed to complete its acquisition of ResApp Diagnostics Pty Ltd and seek reinstatement of its securities on the ASX. | 12/06/2015 |
The company provides a new issue announcement, an application for quotation of additional securities and agreement. | 04/06/2015 |
As approved by Shareholders of Narhex Life Sciences Limited at the General Meeting held on 27 May 2015, the Capital Consolidation on a 3:8 basis has been completed, with the resulting capital structure detailed in the announcement. | 04/06/2015 |
Narhex Life Sciences Limited (ASX: NLS) is pleased to advise in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details of the resolutions and proxies received for the General Meeting held on 27 May 2015. All resolutions were passed on a show of hands including Resolutions 3 and 11 which were passed as special resolutions. | 27/05/2015 |
The securities of Narhex Life Sciences Limited (the "Company") will be suspended from official quotation immediately, pending the outcome of a resolution at the Company's general meeting to approve a change in the Company's activities. The Company's securities will remain suspended pending compliance with Chapters 1 and 2 of the Listing Rules. Security Code: NLS | 27/05/2015 |
the suspension of trading in the securities of Narhex Life Sciences Limited will be lifted before the commencement of trading today, Monday 14 March 2011 | 14/03/2011 |
board confirms that it is in compliance with the Listing Rules | 10/03/2011 |
company lodges various financial reports including Half Year Accounts to 31 December 2010 - they feature a great deal of red ink | 09/03/2011 |
the Company's Deed of Company Arrangement has been wholly effectuated with control of the Company having reverted back to the Directors | 18/01/2011 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 15/11/2010 |
at the GM of the shareholders of Narhex Life Sciences Limited held today in Melbourne, shareholders considered the items of business as set out in the Notice of Meeting dated 5 October 2010 and passed each of resolutions 1 - 7 by a show of hands | 05/11/2010 |
a General Meeting to be held at Level 2, 90 William Street, Melbourne, Victoria, 3000 on 5 November 2010 commencing at 10AM (EST) - this is to consider the proposed recapitalisation of the Company including the consolidation of the Existing Shares in the Company on a 1 for 10 basis | 07/10/2010 |
a Deed of Company Arrangement is executed | 07/05/2010 |
David Ross and Richard Albarran of Hall Chadwick are appointed as administrators of the company - this does not augur well for shareholders | 09/02/2010 |
releases quarterly report | 01/02/2010 |
the Board of Directors advises that Dr Michael Cohen, the Company's Executive Chairman and Acting Managing Director, passed away suddenly overnight | 19/11/2009 |
at the AGM of the shareholders of NLS held today in Melbourne, shareholders passed each of Resolutions no. 1 - 7 as set out in the Notice of Meeting dated 4 September 2009 | 16/10/2009 |
the AGM is to be held at 11:00am Friday 16 October 2009 at the offices of Lander & Rogers, Level 12, 600 Bourke Street, Melbourne Vic 3000 | 17/09/2009 |
releases Half Yearly Report and Accounts to December 2007 and Financial and Annual Report June 2008 | 16/07/2009 |
company responds to an ASX Query re Appendix 4C | 21/11/2008 |
releases Quarterly report for entities admitted on the basis of commitments | 31/10/2008 |
main items in the quarterly cash flow to June 2008 are R&D expense of $103k, an R&D refund of $193k and $114k cash remaining | 31/07/2008 |
the company explains the reasons for its suspension from quotation and provides an update for shareholders | 21/07/2008 |
releases its quarterly cash report to 31 March 2008 showing a deficit at operating level for the quarter of $214k and $12k balance remaining | 30/04/2008 |
securities suspended from quotation following failure to lodge its half report for the period ended 31 December 2007 | 03/03/2008 |
suspension of trading is lifted following receipt of the Company's Full Year Accounts for the period ended 30 June 2007 | 11/10/2007 |
securities suspended from quotation following failure to lodge financial statements for the period to 30 June 2007 | 01/10/2007 |
name changed to ResApp Health Limited | 08/07/2015 |
The Company is pleased to announce that the Share Sale Agreement dated 20 February 2015 between the Company, ResApp Diagnostics Pty Ltd ("ResApp"), the Shareholders of ResApp and UniQuest Pty Ltd has completed with the Company acquiring 100% of ResApp. | 02/07/2015 |
Narhex Life Sciences Limited ("Company") is pleased to announce that its Capital Raising has closed oversubscribed, with funds totalling $4,000,000 having been raised under the Company's Replacement Prospectus dated 26 May 2015. The Company will now proceed to complete its acquisition of ResApp Diagnostics Pty Ltd and seek reinstatement of its securities on the ASX. | 12/06/2015 |
The company provides a new issue announcement, an application for quotation of additional securities and agreement. | 04/06/2015 |
As approved by Shareholders of Narhex Life Sciences Limited at the General Meeting held on 27 May 2015, the Capital Consolidation on a 3:8 basis has been completed, with the resulting capital structure detailed in the announcement. | 04/06/2015 |
Narhex Life Sciences Limited (ASX: NLS) is pleased to advise in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details of the resolutions and proxies received for the General Meeting held on 27 May 2015. All resolutions were passed on a show of hands including Resolutions 3 and 11 which were passed as special resolutions. | 27/05/2015 |
The securities of Narhex Life Sciences Limited (the "Company") will be suspended from official quotation immediately, pending the outcome of a resolution at the Company's general meeting to approve a change in the Company's activities. The Company's securities will remain suspended pending compliance with Chapters 1 and 2 of the Listing Rules. Security Code: NLS | 27/05/2015 |
the suspension of trading in the securities of Narhex Life Sciences Limited will be lifted before the commencement of trading today, Monday 14 March 2011 | 14/03/2011 |
board confirms that it is in compliance with the Listing Rules | 10/03/2011 |
company lodges various financial reports including Half Year Accounts to 31 December 2010 - they feature a great deal of red ink | 09/03/2011 |
the Company's Deed of Company Arrangement has been wholly effectuated with control of the Company having reverted back to the Directors | 18/01/2011 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 15/11/2010 |
at the GM of the shareholders of Narhex Life Sciences Limited held today in Melbourne, shareholders considered the items of business as set out in the Notice of Meeting dated 5 October 2010 and passed each of resolutions 1 - 7 by a show of hands | 05/11/2010 |
a General Meeting to be held at Level 2, 90 William Street, Melbourne, Victoria, 3000 on 5 November 2010 commencing at 10AM (EST) - this is to consider the proposed recapitalisation of the Company including the consolidation of the Existing Shares in the Company on a 1 for 10 basis | 07/10/2010 |
a Deed of Company Arrangement is executed | 07/05/2010 |
David Ross and Richard Albarran of Hall Chadwick are appointed as administrators of the company - this does not augur well for shareholders | 09/02/2010 |
releases quarterly report | 01/02/2010 |
the Board of Directors advises that Dr Michael Cohen, the Company's Executive Chairman and Acting Managing Director, passed away suddenly overnight | 19/11/2009 |
at the AGM of the shareholders of NLS held today in Melbourne, shareholders passed each of Resolutions no. 1 - 7 as set out in the Notice of Meeting dated 4 September 2009 | 16/10/2009 |
the AGM is to be held at 11:00am Friday 16 October 2009 at the offices of Lander & Rogers, Level 12, 600 Bourke Street, Melbourne Vic 3000 | 17/09/2009 |
releases Half Yearly Report and Accounts to December 2007 and Financial and Annual Report June 2008 | 16/07/2009 |
company responds to an ASX Query re Appendix 4C | 21/11/2008 |
releases Quarterly report for entities admitted on the basis of commitments | 31/10/2008 |
main items in the quarterly cash flow to June 2008 are R&D expense of $103k, an R&D refund of $193k and $114k cash remaining | 31/07/2008 |
the company explains the reasons for its suspension from quotation and provides an update for shareholders | 21/07/2008 |
releases its quarterly cash report to 31 March 2008 showing a deficit at operating level for the quarter of $214k and $12k balance remaining | 30/04/2008 |
securities suspended from quotation following failure to lodge its half report for the period ended 31 December 2007 | 03/03/2008 |
suspension of trading is lifted following receipt of the Company's Full Year Accounts for the period ended 30 June 2007 | 11/10/2007 |
securities suspended from quotation following failure to lodge financial statements for the period to 30 June 2007 | 01/10/2007 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 11/06/2014 | Cyril D'Silva | On market | 949,000 | $0.003 | $2,847 |
| 28/02/2014 | Cyril D'Silva | On market | 151,000 | $0.006 | $906 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Adam Sierakowski | Chairman, Non Exec Director | 16/05/2013 |
| Robert Ramsay | Non Exec Director | 20/12/2013 |
| Chris Ntoumenopoulos | Non Exec Director | 22/01/2015 |
| Nicki Farley | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Cyril D'Silva | Executive Chairman | 16/05/2013 | 22/01/2015 |
| Peter Christie | Chairman | 13/01/2011 | 20/12/2013 |
| Simon Lill | Director | 13/01/2011 | 20/12/2013 |
| David Mandel | Director | 17/05/2010 | 20/12/2013 |
| Ian Reynolds | Director | 22/02/2013 | 30/04/2013 |
| Peter Nash | Director | 07/10/2004 | 22/06/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
